TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Ratio Announces an Extension of Their Manufacturing Collaboration With Pharmalogic for FAP-targeted Radiopharmaceuticals

Wednesday, March 13, 2024

Ratio Therapeutics Inc., an emerging player in the pharmaceutical industry focusing on innovative technologies for developing radiopharmaceuticals for cancer treatment and monitoring, has announced an expanded manufacturing collaboration with PharmaLogic. PharmaLogic is a prominent contract development and manufacturing organization (CDMO) specializing in radiopharmaceutical production and distribution. The aim of this partnership is to accelerate the development and commercialization of Ratio's pipeline of next-generation radiotherapies, particularly focusing on Ratio's fibroblast activation protein-alpha (FAP)-targeted radiotherapeutic candidate.

Dr. Matthias Friebe, Chief Technology Officer of Ratio, expressed excitement about the collaboration, emphasizing PharmaLogic's extensive experience in radiopharmaceutical manufacturing and supply chain solutions. He highlighted PharmaLogic's advanced facilities, substantial capacity, and track record of quality and compliance, stating that their expertise in technologies such as accelerated radiochemistry and automation will ensure efficient, scalable production of Ratio's novel therapies to meet future commercial demands. Dr. Friebe sees this collaboration as a significant step towards Ratio Therapeutics' mission of transitioning innovative radiopharmaceuticals to the clinic rapidly, aiming to transform treatment paradigms and improve patient outcomes.

D. Scott Holbrook, Chief Strategy Officer and General Manager at PharmaLogic, echoed Dr. Friebe's sentiments, expressing enthusiasm about supporting Ratio's pipeline of precision-targeted radiotherapies. He emphasized Ratio's leadership in developing radiopharmaceutical solutions with potential improvements in patient outcomes. Holbrook stated that by combining their expertise and manufacturing capabilities, they aim to make these therapies readily available to patients in need.

In collaboration with Lantheus and PharmaLogic, Ratio is conducting a Phase I trial to evaluate the efficacy of a novel FAP-targeted imaging biomarker, copper-64[Cu-64]-labeled LNTH-1363S (formerly RTX-1363S), for PET imaging in adult healthy volunteers. The company recently announced a $50M Series B financing round, expected to drive the clinical advancement of Ratio's first FAP-targeted therapeutic candidate into clinical trials this year.

 

Source: prnewswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit